Aspira Pathlab & Diagnostics Ltd

Aspira Pathlab & Diagnostics has announced its financial results for the quarter ending December 2024, revealing a significant increase in Profit After Tax (PAT) to Rs 1.37 crore, up 194.48% year-on-year. Net sales for the half-year reached Rs 11.59 crore, reflecting a 70.94% growth, indicating strong operational performance.

Aspira Pathlab & Diagnostics has achieved a new 52-week high, reaching Rs. 83.83 on January 14, 2025. The company has outperformed its sector and recorded a substantial weekly gain. Its stock is trading above multiple moving averages, reflecting a strong upward trend and impressive annual performance.

Aspira Pathlab & Diagnostics has achieved a new 52-week high, reaching Rs. 81.69 on January 13, 2025. The company's stock has shown significant momentum, with a cumulative return of 32.94% over the past six days, and has outperformed its sector, reflecting strong market interest and technical strength.

Aspira Pathlab & Diagnostics, a microcap company in the healthcare industry, has seen a surge in its stock price, reaching a 52-week high of Rs.79.7 on November 29, 2024. The stock has shown consecutive gains for the last 6 days, outperforming the Sensex by 81.82% in the past year. This reflects the company's strong performance and potential for growth in the healthcare sector.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has reached a new 52-week high on November 28, 2024. The stock has been performing well, with a current price of Rs.78.16, a 4.5% increase from the previous day. It has outperformed the sector by 4.5% and has been on a consecutive gain for the past 5 days, with a 21.56% increase in returns. The stock also opened with a gain of 4.51% today and is currently trading higher than its moving averages, indicating a positive trend. In comparison to the Sensex, Aspira Pathlab has shown a strong performance with a 1-year return of 78.94%.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has seen a significant increase in its stock price, reaching a 52-week high of Rs.72.99 on November 27, 2024. The company has shown consistent gains in the past four days, with a total return of 10.34%. Despite a 'Sell' call from MarketsMOJO, Aspira Pathlab's stock has been trading above its moving averages, indicating positive sentiment among investors. With a remarkable growth of 74.24% in the past year, the company shows strong potential for future growth.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs.72.35 on November 19, 2024. The stock has outperformed the sector and shown consecutive gains in the past 4 days, with a 16.39% increase. It is currently trading above its moving averages, indicating a positive trend. In the past year, the stock has shown a remarkable 102.86% increase, showcasing the company's strong potential and growth in the market. Investors and market analysts are closely monitoring the company's progress.

Aspira Pathlab & Diagnostics, a microcap company in the healthcare industry, has seen a surge in its stock price, reaching a 52-week high of Rs.69.9 on November 18, 2024. The stock has outperformed the sector by 5.8% and has been on a consecutive gain streak for the last 3 days. It is currently trading higher than its moving averages and has outperformed the Sensex by a significant margin, showcasing its strong growth and potential in the industry.

Aspira Pathlab & Diagnostics, a microcap company in the healthcare industry, has seen a surge in its stock price, reaching a 52-week high of Rs. 65 on November 14, 2024. The stock has consistently outperformed its sector and has shown a positive trend, but investors should exercise caution as the stock call is 'Sell' according to MarketsMOJO.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has reported a positive performance in the quarter ending September 2024. The company's net sales have increased by 82.77% year on year, while its profitability has also shown impressive results. This has led to a 'Sell' call from MarketsMOJO for the company's stock.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs. 63.76 on November 12, 2024. Despite a 'Sell' rating by MarketsMOJO, the stock has outperformed the sector and has shown a strong 1-year performance of 72.32%.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs.62.51 on November 11, 2024. The stock has been on a consecutive gain for the past 3 days and is trading higher than its moving averages, indicating a positive trend. The company has outperformed the Sensex in the past year, showcasing its strong performance and potential for growth in the healthcare industry.

Aspira Pathlab & Diagnostics, a microcap company in the healthcare industry, has seen a surge in its stock price, reaching a 52-week high of Rs.59.82 on November 8, 2024. The stock has outperformed the sector by 3.82% and is currently rated as a 'Sell' by MarketsMOJO. Its positive trend and strong performance in the past year make it a company to watch in the healthcare sector.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs.59.4 on November 7, 2024. The stock has outperformed the sector by 4.53% and has shown a trend reversal after two days of falling. It is currently trading higher than its moving averages and has consistently maintained a stable trend. The company has also outperformed the Sensex by 62.38% in the past year. Investors should conduct their own research and seek professional advice before investing.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has recently hit a 52-week high in its stock price, outperforming the sector by 3.68%. Despite a recent loss, the company has shown strong performance over the past year, indicating potential for growth and stability in the market.

Aspira Pathlab & Diagnostics Ltd, a microcap company in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs.57.3 on November 4th, 2024. The stock has outperformed the sector and is currently trading above its moving averages, indicating a positive trend. Its strong performance over the past year has also surpassed the Sensex's performance.

Aspira Pathlab & Diagnostics, a microcap company in the healthcare industry, has seen a significant increase in its stock price, reaching a 52-week high of Rs. 54.46 on October 24, 2024. The stock has outperformed the sector and consistently traded above its moving averages, showcasing its strong performance and potential in the market.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs. 53.45 on October 23, 2024. The stock has consistently outperformed the sector and is trading above its moving averages, showcasing its potential for growth and market dominance.

Aspira Pathlab & Diagnostics, a microcap company in the hospital and healthcare services industry, has seen a surge in its stock price, reaching a 52-week high of Rs. 51.15 on October 22, 2024. The stock has outperformed the sector by 4% and has shown consecutive gains for the past 2 days. It is currently trading above its moving averages, indicating a positive trend. In the past year, the stock has performed well, showing potential for growth in the future.